Columnistas Expertos

Kenneth Bauer
Columnista Experto de SIIC

Associate Professor of Medicine, Harvard Medical School.Chief, Hematology Section, VA Boston Healthcare System. Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center, Boston, EE.UU.

Artículos publicados (selección):

EXPERIENCIA CLINICA CON FONDAPARINUX: UN NUEVO INHIBIDOR SINTETICO SELECTIVO DEL FACTOR XA
Columnista Experto de SIIC Kenneth Bauer en colaboración con

Fecha de aprobación: 21 de octubre, 2003
Primera edición en siicsalud: 28 de noviembre, 2003
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/20089
Especialidad principal: Hematología

Especialidades relacionadas:

Medicina Farmacéutica,

Medicina Interna,

Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert J-M, van Boeckel CAA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: The first in a new class of antithrombotic agents - the selective factor Xa inhibitors, Cardiovasc Drug Rev 20:37-52, 2002

Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison, Lancet 359:1715-1720, 2002

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison, Lancet 359:1721-1726, 2002

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies, Arch Intern Med 162:1833-1840, 2002

Eriksson BI, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for preventing venous thromboembolism after hip-fracture surgery, N Eng J Med 345:1298-1305, 2001

Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications, Ann Intern Med 135:367-373, 2001

Bauer KA, Eriksson BI, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery, N Eng J Med 345(345):, 2001

Kenneth Bauer

ua40317

Acerca de SIIC

Acceso para suscriptores